Bortezomib and vorinostat in refractory acute myelogenous leukemia and high-risk myelodysplastic syndromes: Produces stable disease but at the cost of high toxicity

Research output: Contribution to journalLetter

6 Scopus citations
Original languageEnglish (US)
Pages (from-to)1789-1791
Number of pages3
JournalLeukemia
Volume27
Issue number8
DOIs
StatePublished - Aug 1 2013

Cite this